FY2025 · period end Dec '25 · from the 10-K filed Mar 2, 2026
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Revenue | $3.31B | $3.11B | $2.74B | $2.54B | $2.23B |
| Gross Profit | — | — | — | — | — |
| Operating Income | $0.39B | $0.35B | $0.33B | $0.35B | $0.30B |
| Net Income | negative: -$0.08B | negative: -$0.17B | negative: -$0.01B | negative: -$0.05B | negative: -$0.07B |
| EPS (Diluted) | negative: -$0.61 | negative: -$1.33 | negative: -$0.09 | negative: -$0.59 | negative: -$1.12 |
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Total Assets | $8.12B | $7.89B | $6.88B | $6.68B | $6.12B |
| Total Liabilities | — | — | — | — | — |
| Stockholders' Equity | $3.13B | $3.20B | $3.03B | $2.94B | $1.97B |
| Cash & Equivalents | $0.24B | $0.27B | $0.20B | $0.28B | $0.39B |
| Total Debt | $3.60B | $3.27B | $2.70B | $2.56B | $2.88B |
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Operating Cash Flow | $0.27B | $0.30B | $0.29B | $0.16B | $0.09B |
| Capital Expenditures | $0.08B | $0.09B | $0.09B | $0.08B | $0.06B |
| Free Cash Flow | $0.20B | $0.21B | $0.20B | $0.08B | $0.03B |
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — |
| Operating Margin | negative: -0.1% | negative: -0.1% | negative: -0.1% | negative: -0.1% | negative: -0.1% |
| Net Margin | negative: -0.0% | negative: -0.1% | negative: -0.0% | negative: -0.0% | negative: -0.0% |
| Return on Equity | negative: -2.5% | negative: -5.4% | negative: -0.4% | negative: -2.2% | negative: -5.0% |
| Return on Assets | negative: -1.0% | negative: -2.3% | negative: -0.2% | negative: -0.9% | negative: -1.2% |
| Debt / Equity | 1.15× | 1.02× | 0.89× | 0.87× | 1.46× |
Showing the most recent 5 annual periods. Get 15 years of history on the Pro plan, or unlimited history back to 1993 plus the smart-money dataset and webhooks on Institutional.
| Form | Accession ID | Report Date | Filing Date | Accepted At | Source |
|---|---|---|---|---|---|
| 8-K | 0001638833-26-000074 | Aug 10, 2026 | Aug 10, 2026 | Aug 10, 2026 11:32 UTC | EDGAR |
| 10-Q | 0001638833-26-000077 | Jun 30, 2026 | Aug 10, 2026 | Aug 10, 2026 20:14 UTC | EDGAR |
| 8-K | 0001638833-26-000069 | Jul 21, 2026 | Jul 24, 2026 | Jul 24, 2026 13:01 UTC | EDGAR |
| 8-K | 0001638833-26-000050 | Jun 5, 2026 | Jun 5, 2026 | Jun 5, 2026 20:50 UTC | EDGAR |
| 10-Q | 0001638833-26-000046 | Mar 31, 2026 | May 5, 2026 | May 5, 2026 20:13 UTC | EDGAR |
| 8-K | 0001638833-26-000044 | May 5, 2026 | May 5, 2026 | May 5, 2026 11:31 UTC | EDGAR |
| 8-K | 0001638833-26-000006 | Mar 2, 2026 | Mar 2, 2026 | Mar 2, 2026 21:55 UTC | EDGAR |
| 10-K | 0001638833-26-000008 | Dec 31, 2025 | Mar 2, 2026 | Mar 2, 2026 22:11 UTC | EDGAR |
Direct links to SEC EDGAR. SGRY has additional filings available on the SEC site.
6 numbers Surgery Partners, Inc. later changed — same XBRL tag, both filings linked.
Revenue from Contract with Customer, Including Assessed Tax·Q3 2018
Notable restatementwas$443.9M
Revised down in a 10-K. Any P/S built on the original was 2.7% too low.
Revenue from Contract with Customer, Including Assessed Tax·Q2 2018
Minor restatementwas$444.8M
Revised down in a 10-K. Any P/S built on the original was 1.9% too low.
Operating Expenses·Q3 2018
Notable restatementwas$398.9M
Revised down in a 10-Q.
Income Tax Expense (Benefit)·Q1 2018
Notable restatementwas$1.8M
Revised up in a 10-Q.
Operating Expenses·Q2 2018
Notable restatementwas$401.2M
Revised down in a 10-Q.
Operating Expenses·Q1 2018
Minor restatementwas$376.2M
Revised down in a 10-Q.
SGRY is not the only one.
See every restatement we've found across the market — or get an alert the next time SGRY revises a number.
Restatements are detected by comparing every vintage of a fact across all of Surgery Partners, Inc.'s filings back to 1993. A revision is not by itself a sign of wrongdoing — companies re-file for many legitimate reasons. This list is not exhaustive: it shows SGRY's most significant revisions, and a figure absent from it has not been certified as unrevised.
Who is buying and selling Surgery Partners, Inc. — insider transactions from Forms 3/4/5/144 and institutional ownership from 13F, 13D, and 13G filings, point-in-time stamped like every other fact in the library. Traders read it as a positioning signal; risk desks read it as concentration.
No published research on SGRY yet.
Reports appear here as analysts publish research on this company — built with Valuein's agentic workflows, every figure pinned to its SEC filing. Be the first: run equity_research_brief on SGRY and publish the result to your public profile.
Ask about Surgery Partners, Inc.
Continue in Workspace — cited answers on SGRY, a thesis you can score, or a signal on the next filing.
Open in WorkspaceGet 15 years of data
Quarterly and annual financials back to 2011 on Pro (1993 on Institutional). Point-in-time accurate with zero survivorship bias.
View plansQuery via Python SDK
Pull data into DuckDB with 3 lines of Python. Works in Jupyter notebooks, scripts, and CI pipelines.
SDK docsConnect via MCP Server
Wire Claude, Cursor, or Codex directly to live SEC data with a single Bearer token. No scraping, no glue code.
MCP docs